Skip to main content
. Author manuscript; available in PMC: 2015 Aug 1.
Published in final edited form as: Nano Today. 2014 Aug 1;9(4):478–498. doi: 10.1016/j.nantod.2014.06.003

Figure 6.

Figure 6

(A) Schematic representation of the designed nanoparticle-mediated drug targeting to bacterial cell walls. The nanoparticles avoid uptake or binding to nontarget cells or blood components at physiologic pH 7.4 due to a slight negative charge and surface PEGylation. The weakly acidic conditions at sites of certain infections activate the surface charge-switching mechanism, resulting in nanoparticle binding to negatively charged bacteria. (B) Nanoparticle zeta potential vs. pH demonstrates notable switching from anionic to cationic with decreases in pH in PLGA-PLH-PEG but not PLGA-PEG nanoparticles. (C) Minimum inhibitory concentrations (MIC) of the different vancomycin formulations in S. aureus. Reprinted with permission from [120]. Copyright 2012, American Chemical Society.